An experimental drug being developed by RedHill Biopharma Ltd. that improved outcomes in a randomized trial involving severely ill COVID-19 patients infected with earlier versions of the coronavirus is showing promise against the Omicron variant in test tube experiments, researchers said. Additionally, people living with well-controlled HIV infections are likely to have immune responses to the mRNA COVID-19 vaccines from Moderna and from Pfizer/BioNTech similar to those of otherwise healthy individuals, according to new data.

A $1 billion fund backed by over 20 drugmakers made its first set of investments on April 4 in two biotechnology startups, nearly two years after it was launched to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.

Venatorx Pharmaceuticals shared that the company’s Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes. 

More than 1.2 million people died in 2019 from infections caused by bacteria resistant to multiple antibiotics, higher than HIV/AIDS or malaria, according to a new report published on January 20.

Klick Health and Lakeridge Health introduced a technologically advanced medication dosage calculator to help pharmacists and physicians determine the correct amount of vancomycin for treating life-threatening, antibiotic-resistant, bacterial infections.

In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.

Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).

None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.

In the RELATIVITY-047 Phase II/III trial combining Bristol Myers Squibb’s Opdivo with the anti-LAG-3 antibody relatlimab, the drug mashup met the study’s primary goal for progression-free survival compared to use of the blockbuster brand alone in metastatic melanoma patients.

A majority of Covid-19 patients that were admitted to U.S. hospitals during the first few months of the pandemic were prescribed antibiotics even before a bacterial infection had been confirmed, a study showed on March 10.